Fig 1.
Enrollment of households and household residents in a survey of chikungunya virus seroprevalence among communities with (A) or without (B) autocidal gravid ovitraps (AGO traps) in Puerto Rico, November 2015–February 2016.
Table 1.
Comparison of demographic characteristics and reported behaviors among participants of a survey of chikungunya virus seroprevalence among communities with (intervention) or without (non-intervention) autocidal gravid ovitraps (AGO traps) in Puerto Rico, November 2015–February 2016.
Table 2.
Proportion of residents with serologic evidence of chikungunya virus infection from communities with (intervention) or without (non-intervention) autocidal gravid ovitraps (AGO traps) by demographic and behavioral characteristics, Puerto Rico, November 2015–February 2016.
Fig 2.
Estimated proportion of chikungunya virus infected residents of communities in Puerto Rico with (intervention; n = 175) or without (non-intervention; n = 152) autocidal gravid ovitraps (AGO traps) by reported number of daylight hours spent at home per week, November 2015–February 2016.
Abbreviations: PR = prevalence ratio; error bars indicate standard error.
Table 3.
Demographic and behavioral characteristics associated with chikungunya virus infection among survey participants from four communities in Puerto Rico, November 2015–February 2016.
Table 4.
Association of illnesses and disability with chikungunya virus infection among residents of four communities in Puerto Rico, November 2015–February 2016.
Fig 3.
Number of participants with evidence of chikungunya virus infection who reported fever with arthralgia by month and year of illness onset (N = 81*), and number of mosquito pools in which chikungunya virus RNA was detected by RT-PCR (N = 50) from communities with (intervention) or without (non-intervention) autocidal gravid ovitraps (AGO traps) in Puerto Rico, November 2015–February 2016.
*As reported during the serosurvey; 3 participants had unknown timing of illness onset.